The TRAIL apoptotic pathway in cancer onset, progression and therapy.
about
Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2Molecular functions of thyroid hormones and their clinical significance in liver-related diseasesTRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavagesDJ-1 inhibits TRAIL-induced apoptosis by blocking pro-caspase-8 recruitment to FADDMatrix protein CCN1 is critical for prostate carcinoma cell proliferation and TRAIL-induced apoptosisPotential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer ImmunotherapyDepolarization Controls TRAIL-Sensitization and Tumor-Selective Killing of Cancer Cells: Crosstalk with ROSRole of apoptosis in diseaseER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosisCARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cellsNovel phosphorylation and ubiquitination sites regulate reactive oxygen species-dependent degradation of anti-apoptotic c-FLIP proteinMathematical modelling of cell-fate decision in response to death receptor engagementStochastic competition between mechanistically independent slippage and death pathways determines cell fate during mitotic arrestTRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress ResponsePuma and Trail/Dr5 pathways control radiation-induced apoptosis in distinct populations of testicular progenitorsParadoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cellsEvolving Therapies and FAK Inhibitors for the Treatment of CancerA set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer.The E. coli effector protein NleF is a caspase inhibitor.Inducing apoptosis in rolling cancer cells: a combined therapy with aspirin and immobilized TRAIL and E-selectinModulating cell-to-cell variability and sensitivity to death ligands by co-drugging.Identification of miRNA-7 by genome-wide analysis as a critical sensitizer for TRAIL-induced apoptosis in glioblastoma cells.Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteinsCyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.Enhancement of TRAIL-induced apoptosis by 5-fluorouracil requires activating Bax and p53 pathways in TRAIL-resistant lung cancers.Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.X-linked ectodermal dysplasia receptor is downregulated in breast cancer via promoter methylation.Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancermiR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinomaPPARγ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy fluxEngineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cellsPlasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells.Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells.Targeting a novel N-terminal epitope of death receptor 5 triggers tumor cell death.Potentiation of tumor necrosis factor-alpha-induced tumor cell apoptosis by a small molecule inhibitor for anti-apoptotic protein hPEBP4microRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancerTNFα cooperates with IFN-γ to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis.TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitroThe combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines.
P2860
Q21133690-D27DA548-D009-4727-9045-FC6077E89161Q21284820-2867535F-6ED6-4026-B57B-9D967EBA9B80Q23910293-C727E822-949C-4A9B-A728-0CECDD6316AEQ24316876-E447FF0D-9422-4018-8FA9-BF472E419E09Q24647641-94AD42EA-B07E-46D8-87EE-A0F165D76338Q26771601-99FB0D76-1BE9-4C5F-9F71-92F1F0200A8FQ26772347-2E984803-B864-463B-BCEE-EF4D1432001BQ26853365-54F5090C-FBBC-4C9D-910B-ACC1E32AB375Q26865637-ACB6EF12-EB44-4FAC-9E37-BBD04F399677Q28386923-22536F83-356E-48D6-A92F-0BE3E0582AFCQ28396942-4C127ECF-479E-463B-BC31-66F34FEA289DQ28397635-B6FE0729-6859-404E-B20B-66BCA845A286Q28473094-B73FA39F-D91B-4476-9976-557228C17782Q28476597-7C3CC0AF-9CF8-4423-AD07-8369B5732338Q28548386-C0B895FB-1196-4E2B-AAFE-EABF5E5728BDQ28749705-3D27BA88-728D-415B-B8BF-571A74477F77Q28833514-75EB204A-8F80-426C-9FCA-C0D324856BDAQ28972291-1074F62F-D26D-4C87-9DB6-4CB5A4555545Q30361915-85DA63B3-C450-40A7-895C-E1F625971980Q30456165-87D86091-BFD3-4D0C-A017-A49247BF72C1Q30523992-3EFF5FC1-645C-47A4-959B-BC4DCA9BE4B3Q30544925-C5C2B4E0-0986-4380-A245-7297C412E616Q30854013-4A9BB5F5-88FD-4655-97CD-3BBF3ACB9B98Q33485621-377AF0C0-88E4-4C30-BDE6-AC4D2F08D6BBQ33502208-6B21B47D-5FFC-4A7D-842B-D5FF7E94C110Q33566824-A2F81E57-F369-43A6-916B-BD3C776A171DQ33569854-22AC6982-2518-4AE6-A8D4-BABCDC28127BQ33658266-3995BD10-636F-42A1-9615-7F9C83D52D5FQ33658593-335A94C7-FD5C-472A-8A27-E315EC0C40F8Q33661028-5B5FCB00-8DDC-4869-A59C-04A31831E78EQ33688828-A9DFD9C7-CFF2-4D4A-852C-6A9B72BB4ADFQ33689870-4C61266F-0841-48DF-8B7B-0D16A276EFE7Q33695003-C33E8587-14F0-4EFF-A152-B596E131BD01Q33709701-3436D349-CFCF-461F-BA9E-A5BD515BDBE8Q33726537-91F69B0D-78FB-4EC5-8896-B7B0E225B3ECQ33782589-BF0855EC-428D-487B-A036-1A5C026CB4B2Q33784290-ED0DF507-B4BA-4E13-8F92-F010BB650117Q33802588-36306C23-12A9-420A-8E99-F527591E5625Q33802751-05555767-5B60-4544-926B-9A2603E11C61Q33815463-082E9BF1-FAEC-4C23-A784-235B1B9AF529
P2860
The TRAIL apoptotic pathway in cancer onset, progression and therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The TRAIL apoptotic pathway in cancer onset, progression and therapy.
@en
The TRAIL apoptotic pathway in cancer onset, progression and therapy.
@nl
type
label
The TRAIL apoptotic pathway in cancer onset, progression and therapy.
@en
The TRAIL apoptotic pathway in cancer onset, progression and therapy.
@nl
prefLabel
The TRAIL apoptotic pathway in cancer onset, progression and therapy.
@en
The TRAIL apoptotic pathway in cancer onset, progression and therapy.
@nl
P356
P1476
The TRAIL apoptotic pathway in cancer onset, progression and therapy.
@en
P2093
Ailsa J Frew
P2888
P304
P356
10.1038/NRC2465
P407
P577
2008-10-01T00:00:00Z